What is Generate Biomedicines, Inc. 's D&A?

Generate Biomedicines, Inc. (GENB) reported D&A of $3.27M in Q1 2026.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Generate Biomedicines, Inc. GENB D&A

D&A at other companies

MYR GroupMYRG

$16.55M+10.3%

NNN REITNNN

$70.8M+9.6%

Piper SandlerPIPR

$4.73M+12.4%

RepligenRGEN

$19.76M+5.7%

American Healthcare REITAHR

$67.06M+63.1%

LKQLKQ

$99M-1.0%

Other financials

Income statement

See full

Revenue$7.2M-18.1%

Operating income-$64.1M-33.1%

Net income-$61.4M-47.4%

EPS (diluted)-$1.07+34.0%

Balance sheet

See full

Cash & equivalents$160.6M-27.2%

Total debt$65.6M—

Total equity$514.8M+209%

Total assets$625.7M—

Cash flow

See full

Operating cash flow-$80.4M-51.2%

CapEx$3.8M+403%

Free cash flow-$84.2M-56.1%

Valuation

See full

Market cap$1.86B—

Enterprise value$1.76B—

Returns & leverage

See full

Debt / equity0.1×—

Current ratio9.2×—

Where this comes from

Reported directly by Generate Biomedicines, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Generate Biomedicines, Inc. ’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Generate Biomedicines, Inc. 's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Generate Biomedicines, Inc. 's D&A?: Generate Biomedicines, Inc. (GENB) reported D&A of $3.27M in Q1 2026.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.